Combination bicalutamide and everolimus may be efficacious in men with bicalutamide-naïve castration-resistant prostate cancer (CRPC), according to a study published in Cancer.1
However, these patients may be at high risk of experiencing everolimus-related toxicity.
Researchers led by Helen Chow, MD, of the University of California Davis in Sacramento looked at 24 patients with a mean age of 71.1 years who had serum testosterone levels less than 50 ng/dL and no prior bicalutamide or everolimus use. Patients were given oral bicalutamide 50 mg and oral everolimus 10 mg once daily, during each 4-week cycle.
Primary endpoint was prostate-specific antigen (PSA) response from baseline.
RELATED: Open, Robot-assisted Radical Prostatectomy Linked With Favorable Outcomes
Among the observed patients, 18 were found have a PSA response, whereas 15 had a PSA decrease of at least 50%. Median overall survival was found to be 28 months, and 14 patients developed grade 3 or grade 4 adverse events that were attributable to treatment.
- Chow H, Ghosh PM, deVere White R, et al. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer [published online ahead of print March 28, 2016]. Cancer. doi: 10.1002/cncr.29927.